CAR T-cell Therapy: Indications, Management, and Future Directions

Wednesday, November 19, 2025, 9:00 AM - Sunday, November 19, 2028, 10:00 AM

ANCC Nursing Contact Hours (1.00 hours), General Attendance (1.00 hours)

Chimeric Antigen Receptor T-Cell Therapy is rapidly emerging through numerous research trials. Dr. Charles Gaulin speaks on the indications, management and future directions that are involved with CAR-T Cell Therapy.

Presenter

Charles J. Gaulin MD
Staff Physician
Hematology
Dartmouth Hitchcock Medical Center

1. Identify at least three indications for CAR T-cell therapy.
2. Describe the side effects and adverse effects of CAR T-cell therapy, including effective management strategies.
3. Discuss the future implications of CAR T-cell therapy for clinical practice and patient care.

In support of improving patient care, Dartmouth Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

American Nurses Credentialing Center (ANCC)
Dartmouth Health designates this Enduring Material for a maximum of 1.00 ANCC contact hours.

Other learners

All other learners may claim General Attendance credit. Consult your professional licensing board regarding the applicability and acceptance of General Attendance credit for programs certified for credit by organizations accredited by Joint Accreditation for Interprofessional Education.

Registration/Requirements for Successful Completion
You may claim credit for successful completion of this online course. In order to claim credit, you must follow these steps:

1. Click the Register tab above. If you are not logged into your account, you will need to log in. Use the Forgot Your Password? button if you need to reset your password.

2. Register for the activity.

3. Click the Content/Tests tab and then View Content to view the recording. View the entire presentation.

4. Complete the Post-Test (attestation - return to the Content/Tests tab to find it).

5. Click the Complete Evaluation button, or click My Account in the menu bar; then click Evaluations.

6. Complete and Submit the Evaluation.

Bibliographic Material

• Ceja J, et al. Title not specified. J Exp Med. 2024;221(2):e20230903. https://doi.org/10.1084/jem.20230903

• Fortin Ensign SP, Gaulin C, et al. Evaluating the patient with neurotoxicity after chimeric antigen receptor T-cell therapy. Curr Treat Options Oncol. 2022;23:1845-1860. https://doi.org/10.1007/s11864-022-00994-2

• Hill JA, Seo SK. How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies. Blood. 2020;136(8):925-935. https://doi.org/10.1182/blood.2019004000

• Kawalekar OU, O’Connor RS, et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity. 2016;44(2):380-390. https://doi.org/10.1016/j.immuni.2016.01.006

• Morris EC, Neelapu SS, Giavridis T, et al. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2022;22:85-95. https://doi.org/10.1038/s41577-021-00547-6

• Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol. 2020;17(3):147-167. https://doi.org/10.1038/s41571-019-0297-y

• Yañez L, Alarcón A, Sánchez-Escamillia M, Perales MA. How I treat adverse effects of CAR-T cell therapy. ESMO Open. 2020;4(Suppl 4):e000746. https://doi.org/10.1136/esmoopen-2020-000746
  
  

Provider Contact Information
Provider contact information for questions regarding accreditation of the activity:

Center for Learning and Professional Development
ACE Office
Dartmouth Health
[email protected]

Mitigation of Relevant Financial Relationships

Dartmouth Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education.  Any individuals in a position to control the content of a CE activity, including planners, faculty, authors, or others are required to disclose all financial relationships with ineligible companies^.  All relevant financial relationships have been mitigated prior to the commencement of the activity.

^Ineligible Company is any entity whose primary business purpose is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.